Mutation Profile as Translatable Prognostic Biomarker of Uveal Melanoma

University Of Pennsylvania, Philadelphia PA

Investigators

Linked publications & trials

Abstract

DESCRIPTION (provided by applicant): Uveal melanoma (UM) is highly resistant to current therapies. We hypothesize that precursors of metastatic UM cells are present at a small level in the primary tumor. The level of the mutation bearing cells is related to tumor heterogeneity implying the presence of multiple clones with different mutation spectrums. These cells evolve over time as a function of therapy and a variety of host factors. We will use the methods of next generation sequencing to take an unbiased look at the whole exome followed by cancer exome of multiple tumor genomes. The first objective is to define the somatic mutation profile of metastatic UM and compare the profiles of matched primary and metastatic lesions to see which mutations are selected in the metastatic lesions. In addition, identify mutations in known cancer associated genes, which may be present at very high (common) or low levels (rare), in the primary tumor and selected in metastatic UM. The second objective is to compare the mutation profiles of different sections of the same tumors selected based on the size and cell type profiles. This will detect different frequencies of mutations, if present, in the sections and defie intra-tumor heterogeneity. The third objective is to compare identified intra-tumor heterogeneity to other known genetic, clinical and histological features of the tumor as prognostic markers. The clinical relevance can be the knowledge that one biopsy of a large tumor does not provide enough information about the array of mutations present to design clinical trials or treatments based on the genetic profile of the tumor. In addition, the results may lead to novel therapeutic targets in UM.